School of Pharmacy, Division of Pharmaceutical Sciences, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI 53705, USA; Department of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Adv Healthc Mater. 2013 Dec;2(12):1544-63. doi: 10.1002/adhm.201300063. Epub 2013 Jul 5.
This Progress Report reviews recent advances in the utility of extracellular matrix (ECM)-mimic biomaterials in presenting and delivering therapeutic cells to promote tissue healing. This overview gives a brief introduction of different cell types being used in regenerative medicine and tissue engineering while addressing critical issues that must be overcome before cell-based approaches can be routinely employed in the clinic. A selection of five commonly used cell-associated, biomaterial platforms (collagen, hyaluronic acid, fibrin, alginate, and poly(ethylene glycol)) are reviewed for treatment of a number of acute injury or diseases with emphasis on animal models and clinical trials. This article concludes with current challenges and future perspectives regarding foreign body host response to biomaterials and immunological reactions to allogeneic or xenogeneic cells, vascularization and angiogenesis, matching mechanical strength and anisotropy of native tissues, as well as other non-technical issues regarding the clinical translation of biomatrix/cell-based therapies.
本进展报告回顾了细胞外基质（ECM）模拟生物材料在呈现和输送治疗细胞以促进组织愈合方面的最新应用进展。本综述简要介绍了再生医学和组织工程中使用的不同细胞类型，同时解决了在细胞疗法常规应用于临床之前必须克服的关键问题。选择了五种常用的细胞相关生物材料平台（胶原、透明质酸、纤维蛋白、藻酸盐和聚（乙二醇）），用于治疗多种急性损伤或疾病，重点介绍了动物模型和临床试验。本文最后讨论了生物材料的异物宿主反应和同种异体或异种细胞的免疫反应、血管生成和血管生成、匹配天然组织的机械强度和各向异性、以及生物基质/基于细胞的治疗转化的其他非技术问题等当前挑战和未来展望。
